MyChesCo on MSN

Gene therapy slows vision loss in Stargardt trial, fueling hope for first treatment

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) said newly published clinical trial data support the safety and early effectiveness ...

Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy

Study supports favorable safety and tolerability profile and clinically meaningful functional and structural benefits in Stargardt disease ...
Ophthalmology Times

Opus Genetics launches phase 1/2 MERTK gene therapy trial

Opus Genetics is conducting a trial for OPGx-MERTK gene therapy in Abu Dhabi, targeting MERTK-related retinitis pigmentosa ...
Fierce Biotech

Ocugen posts midphase gene therapy data, charting course for rivalry with Apellis, Astellas

Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...
Stocktwits on MSN

OCGN stock rises pre-market after gene therapy data shows promise in rare eye disorder

Ocugen Inc. (OCGN) shares rose nearly 3% pre-market on Monday after the company announced results in its gene therapy trial for Stargardt patients with no options. Ocugen announced positive Phase 1 ...
GEN

3 BLAs in 3 Years: Ocugen Sees Potential in Eye Disease Gene Therapies

Ocugen says it is on track to reshape the market for gene therapies against eye disorders over the next three years, by working to bring to market three treatments for blindness-related diseases, two ...
Nasdaq

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy ...

MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that ...
WJHL-TV

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

MALVERN, Pa., July 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that ...

Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious ...